(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage
biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary
technological platform DOS47, is pleased to announce that it has successfully closed its Early Warrant Exercise
Incentive Program (the “Incentive Program”) and Extension of Warrant Exercise Period (“Warrant Extension”),
previously announced on March 11, 2022 and April 13, 2022. The Company has received gross proceeds of
$3,210,204 from the exercise of 12,346,938 share purchase warrants at $0.26 per share.
- 0 Comments
- FY2022